- Home
- GPI vs HCM Comparison
GPI vs HCM Comparison
Compare GPI & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GPI | HCM |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GPI | HCM |
|---|---|---|
| Price | $240.26 | $13.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $346.42 | $20.59 |
| AVG Volume (30 Days) | ★ 268.2K | 46.6K |
| Earning Date | 10-28-2026 | 07-30-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 19.50 | N/A |
| Revenue | ★ $11,123,721,000.00 | N/A |
| Revenue This Year | N/A | $14.24 |
| Revenue Next Year | $5.58 | $11.52 |
| P/E Ratio | $11.71 | ★ $5.49 |
| Revenue Growth | ★ 2.17 | N/A |
| 52 Week Low | $225.51 | $9.77 |
| 52 Week High | $461.27 | $16.33 |
Technical Indicators
Market Signals| Indicator | GPI | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 51.51 |
| Support Level | N/A | $12.90 |
| Resistance Level | $257.07 | $14.44 |
| Average True Range (ATR) | 9.17 | 0.34 |
| MACD | 0.15 | -0.14 |
| Stochastic Oscillator | 44.57 | 35.76 |
Price Performance
Historical ComparisonAbout GPI Group 1 Automotive Inc.
Group 1 owns and operates 32 collision centers and over 250 automotive dealerships in the US and the UK, offering 36 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 31.6% of new-vehicle unit volume in 2025 and the UK 27.6%. Texas, Massachusetts, and California combined was 45.4%. Revenue in 2025 totaled $22.6 billion. The firm entered the UK in 2007 and has 106 stores there contributing about 26% of total revenue. Group 1 was founded in 1995 and is based in Houston.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.